Seyfarth Synopsis: Two recent decisions on motions to dismiss in COVID-related class action securities litigations—one successfully dismissed, the other largely surviving—show that a bare allegation of failure to predict the...more
Seyfarth Synopsis: The Delaware Chancery Court’s October 1 In re Clovis decision marks the second time in 2019 that a Delaware court has permitted a Caremark duty-to-monitor derivative claim against directors—considered...more
11/1/2019
/ Caremark claim ,
Clinical Trials ,
Compliance Management Systems ,
Corporate Counsel ,
Derivative Suit ,
Directors ,
Duty to Monitor ,
Failure to Monitor ,
Motion to Dismiss ,
Pharmaceutical Industry ,
Prescription Drugs ,
Shareholder Litigation